GHRP-2 vs PT-141
Head-to-head comparison of GHRP-2 (Growth Hormone Releasing Peptide-2) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
| Property | GHRP-2 | PT-141 |
|---|---|---|
| Category | Performance | Performance |
| Full Name | Growth Hormone Releasing Peptide-2 | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 817.97 Da | 1,025.2 Da |
| Half-Life | ~25 minutes | ~2.7 hours |
| Amino Acids | 6 | 7 |
| Typical Dose | 100-300 mcg | 1.75 mg |
| Route | SC / IV | SC |
| Purity | — | — |
| Studies Count | 172 | 178 |
| Research Status | Approved (Japan) | FDA Approved |
GHRP-2 Benefits
- ✓Potent GH release (stronger than GHRP-6)
- ✓Less appetite stimulation than GHRP-6
- ✓Improved body composition
- ✓Enhanced deep sleep quality
- ✓Cytoprotective properties
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
GHRP-2 Dosing
Standard: 100-300 mcg SC 2-3 times daily|Pre-bed: 100-200 mcg for GH pulse during sleep|Combined: 100 mcg with CJC-1295 for synergy|Cycle: 8-16 weeks, 4 weeks off
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
GHRP-2 Side Effects
- ⚠Common: Mild appetite increase, water retention, tingling
- ⚠Moderate: Cortisol elevation at higher doses
- ⚠Rare: Prolactin increase, transient dizziness
- ⚠Better tolerated than GHRP-6 overall
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
GHRP-2
GHRP-2 has strong clinical evidence. Approved in Japan for diagnostic use. Multiple human studies confirm reliable GH stimulation with a favorable side effect profile compared to GHRP-6.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.